Heart failure & cardiomyopathiesSecondary analysis
Hemocompatibility Outcomes With Pharmacological Therapy Following Left Ventricular Assist Device (LVAD) Implantation
- Secondary analysis of the ARIES-HM3 randomised trial
- exploratory
Authors' conclusion
Background pharmacologic therapy did not modify the effect of aspirin on HRAE; however, the use of a RAAS inhibitor was independently associated with a reduction in HRAE.
Study context
- Population
- Patients with a HeartMate 3 LVAD in the ARIES-HM3 trial, discharged, non-inotrope-dependent, completing 1-month follow-upof 589 randomized
- Participants
- 547 patients
- Comparison
- Background pharmacotherapy on vs off prescription
- Primary endpoint
- Primary endpoint success
Primary result
Primary endpoint success by RAAS inhibitor use · 12 months
Hazard ratio
0.61
95% CI 0.37–1.01
P = 0.14
By group
RAAS inhibitors vs No RAAS inhibitors
HR 0.61 (95% CI 0.37–1.01); P = 0.14
As reported in the abstract
- No significant interaction with aspirin use on primary endpoint: RAAS inhibitors
- P = 0.08
- No significant interaction with aspirin use on primary endpoint: other HF-related therapies
- P = 0.65
- No significant interaction with aspirin use on primary endpoint: other CV drugs
- P = 0.92
Further findings
Primary endpoint success, other HF-related therapy (on vs off)
- Not associated with primary event success: on vs off
- 75.4% vs 76.7%
Primary endpoint success, other CV drugs (on vs off)
- Not associated with primary event success: on vs off
- 74.3% vs 81.3%
BP control
- No significant interaction: RAAS inhibitors
- P = 0.69
- No significant interaction: other HF-related therapy
- P = 0.40
Original publication
Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation. JACC Heart Fail. Published 19 November 2025. doi:10.1016/j.jchf.2025.102769
Summarised from the published abstract; every number is checked against it